Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents

BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma associated with poor prognosis. Implementation of high-dose cytarabine (araC) into induction therapy became standard-of-care for all newly diagnosed younger MCL patients. However, many patients relapse even a...

Descripción completa

Detalles Bibliográficos
Autores principales: Klanova, Magdalena, Lorkova, Lucie, Vit, Ondrej, Maswabi, Bokang, Molinsky, Jan, Pospisilova, Jana, Vockova, Petra, Mavis, Cory, Lateckova, Lucie, Kulvait, Vojtech, Vejmelkova, Dana, Jaksa, Radek, Hernandez, Francisco, Trneny, Marek, Vokurka, Martin, Petrak, Jiri, Klener, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094598/
https://www.ncbi.nlm.nih.gov/pubmed/24972933
http://dx.doi.org/10.1186/1476-4598-13-159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094598/
https://www.ncbi.nlm.nih.gov/pubmed/24972933
http://dx.doi.org/10.1186/1476-4598-13-159

Ejemplares similares